Potential mechanism of interleukin-8 production from lung cancer cells: An involvement of EGF-EGFR-PI3K-Akt-Erk pathway

Journal of Cellular Physiology

Volumn 227, Issue 1, 2012, Pages 35-43

  Zhang, Yong ^a   Wang, Linyan ^a   Zhang, Miaomiao ^a   Jin, Meiling ^a   Bai, Chunxue ^a   Wang, Xiangdong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHBM 1009; UNCLASSIFIED DRUG;

CANCER CELL; CELL PROLIFERATION; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; EPIDERMAL GROWTH FACTOR; HUMANS; INTERLEUKIN-8; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 79961173874     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22722     Document Type: Review

References (31)

1. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J. 2006. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 54:25-33.
2. Bader AG, Kang S, Zhao L, Vogt PK. 2005. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5:921-929.
3. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Basolo F, Pingitore R, Fontanini G. 2005. Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. Lung Cancer 50:309-317.
4. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. 2005. Tumor-associated macrophages: The double-edged sword in cancer progression. J Clin Oncol 23:953-964.
5. Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A. 2010. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum Pathol 42:214-226.
6. Downward J. 2008. Targeting RAS and PI3K in lung cancer. Nat Med 14:1315-1316.
7. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, Cooper K, Walker D, McWilliams A, Liu G, Szabo E, Brody J, Massion PP, Lenburg ME, Lam S, Bild AH, Spira A. 2010. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2:26ra25.
8. Hynes NE, MacDonald G. 2009. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184.
9. Le QC, Guenon I, Gillon JY, Lagente V, Boichot E. 2008. MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells. Am J Physiol Lung Cell Mol Physiol 294:L1076-L1084.
10. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH. 2010a. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol 632:23-32.
11. Lee MF, Wang NM, Liu SW, Lin SJ, Chen YH. 2010b. Induction of interleukin 8 by American cockroach allergens from human airway epithelial cells via extracellular signal regulatory kinase and jun N-terminal kinase but not p38 mitogen-activated protein kinase. Ann Allergy Asthma Immunol 105:234-240.
12. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S. 2008. Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem 283:9977-9985.
13. Lu ZJ, Zhou Y, Song Q, Qin Z, Zhang H, Zhou YJ, Gou LT, Yang JL, Luo F. 2010. Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways. Cell Physiol Biochem 26:609-618.
14. Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436-444.
15. McGovern T, Risse PA, Tsuchiya K, Hassan M, Frigola G, Martin JG. 2010. LTD4 induces HB-EGF-dependent CXCL8 release through EGFR activation in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 299:L808-L815.
16. Moody TW, Berna MJ, Mantey S, Sancho V, Ridnour L, Wink DA, Chan D, Giaccone G, Jensen RT. 2010. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol 637:38-45.
17. Mukaida N. 2000. Interleukin-8: An expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 72:391-398.
18. Pawson T. 2004. Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116:191-203.
19. Roberts PJ, Der CJ. 2007. Targeting the Raf-ERK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
20. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, Iguchi H, Noda M. 2011. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 28:13-25.
21. Shi Y, Chen L, Li J, Lv YL, Sun Q, Wang LX, Jiao SC. 2011. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 32:381-390.
22. Su JC, Lin KL, Chien CM, Tseng CH, Chen YL, Lin SR. 2010. Naphtho[1, 2-b]furan-4, 5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. Life Sci 86:207-213.
23. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, Yamashita Y, Kanemura M, Ueda M, Sugita M, Franklin WA, Ohmichi M. 2011. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 11:50-57.
24. Toimela T, Tahti H, Ylikomi T. 2008. Comparison of an automated pattern analysis machine vision time-lapse system with traditional endpoint measurements in the analysis of cell growth and cytotoxicity. Altern Lab Anim 36:313-325.
25. Trusolino L, Bertotti A, Comoglio PM. 2001. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107:643-654.
26. Wang XD, Li K, Chen H, Wang D, Zhang Y, Bai C. 2010. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med 14:833-839.
27. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF. 2008. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68:6913-6921.
28. Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW. 2008. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 60:166-174.
29. Yuan A, Chen JJ, Yao PL, Yang PC. 2005. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 10:853-865.
30. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF. 2010. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol.
31. Zlotnik A, Yoshie O. 2000. Chemokines: A new classification system and their role in immunity. Immunity 12:121-127.